You are here

  • Home
  • Archive
  • Volume 25, Issue 2
  • Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors

Article info

Article menu

Download PDFPDF

EBM verdict
General medicine
Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
Free

Authors

  • Jack W O’Sullivan Division of Cardiology, Department of Medicine, Stanford University, Palo Alto, California, USA Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jack W O’Sullivan, Division of Cardiology, Department of Medicine, Stanford University, Palo Alto, CA 94305, USA; jackos{at}stanford.edu
View Full Text

Citation

O’Sullivan JW
Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
BMJ Evidence-Based Medicine 2020;25:79-80.

Publication history

  • Accepted July 18, 2019
  • First published July 31, 2019.
Online issue publication 
June 15, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.